Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Novel Tools to Improve the Challenging Diagnosis of Ph-like ALL. Comparison between Optical Genome Mapping and Digital-MLPA

Gianfranco Lapietra, Deborah Cardinali, Adela Cisneros, Marco Beldinanzi, Alberto Hernández Sánchez, Francesca Kaiser, Jordi Ribera, Josgrey Del Valle Del Valle Navas Acosta, Jesus Maria Hernandez Rivas, Anna Torrent, Isabel Granada, Jose Tomas Navarro, Robin Foà, Maurizio Martelli, Alberto Orfao, Josep-Maria Ribera, Sabina Chiaretti

Blood (2024) 144 (Supplement 1): 5919.

https://doi.org/10.1182/blood-2024-208697

Published: 2024

Journal Articles

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Blood (2024) 144 (Supplement 1): 962.

https://doi.org/10.1182/blood-2024-205124

Published: 2024

Journal Articles

Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Gianfranco Lapietra, Jordi Ribera, Mireia Morgades, Neus Ruiz Xiville, Anna Torrent, Mar Mallo, Jesus Maria Hernandez Rivas, Alberto Hernández Sánchez, Alberto Orfao, Isabel Granada, Jose Tomas Navarro, Ilaria Del Giudice, Maurizio Martelli, Sabina Chiaretti, Josep-Maria Ribera

Blood (2024) 144 (Supplement 1): 2844.

https://doi.org/10.1182/blood-2024-208425

Published: 2024

Journal Articles

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Blood (2024) 144 (Supplement 1): 1437.

https://doi.org/10.1182/blood-2024-207954

Published: 2024

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2023-182163

Published: 2023

Journal Articles

Development of a Modified Prognostic Index for Adult Patients with Acute Lymphoblastic Leukemia

Eduardo Cerello Chapchap, Ana Luisa Oliveira, Maria Eduarda Alonso Joaquim de Carvalho, Mireia Morgades, Vitor AQ Mauad, Davimar Miranda Maciel Borducchi, Fabio P. S. Santos, Jordi Ribera, Fabio R. Kerbauy, Josep-Maria Ribera, Nelson Hamerschlak

Blood (2023) 142 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2023-184869

Published: 2023

Journal Articles

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Blood (2022) 140 (Supplement 1): 6345–6347.

https://doi.org/10.1182/blood-2022-162159

Published: 2022

Journal Articles

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Josep-Maria Ribera, Olga Garcia, Jordi Ribera, Pau Montesinos, Isabel Cano, Pilar Martínez, Jordi Esteve, Daniel Esteban, María García-Fortes, Natalia Alonso, José González-Campos, Arancha Bermúdez, Anna Torrent, Eulàlia Genescà, Santiago Mercadal, Joaquín Martínez-López, Ramon Garcia-Sanz

Blood (2021) 138 (Supplement 1): 1230.

https://doi.org/10.1182/blood-2021-148310

Published: 2021

Journal Articles

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Blood (2021) 138 (Supplement 1): 3486.

https://doi.org/10.1182/blood-2021-148263

Published: 2021

Journal Articles

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulàlia Genescà, Pere Barba, Jordi Ribera, Irene García-Cadenas, María José Moreno, Daniel Martínez-Carballeira, Anna Torrent, Pilar Martínez-Sánchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, María Teresa Artola, Marta Cervera, José González-Campos, Carlos Rodríguez, Arancha Bermúdez, Andrés Novo, Beatriz Soria, Rosa Coll, María-Luz Amigo, Aurelio López-Martínez, Rosa Fernández-Martín, Josefina Serrano, Santiago Mercadal, Antònia Cladera, Alberto Giménez-Conca, María-Jesús Peñarrubia, Eugènia Abella, Ferran Vall-llovera, Jesús-María Hernández-Rivas, Antoni Garcia-Guiñon, Juan-Miguel Bergua, Beatriz de Rueda, María-José Sánchez-Sánchez, Alfons Serrano, María Calbacho, Natalia Alonso, Jose-Ángel Méndez-Sánchez, Raimundo García-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao

Blood (2021) 137 (14): 1879–1894.

https://doi.org/10.1182/blood.2020007311

Published: 2021

Includes: Supplemental data

Journal Articles

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-137383

Published: 2020

Journal Articles

Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial

Blood (2019) 134 (Supplement_1): 826.

https://doi.org/10.1182/blood-2019-123613

Published: 2019

Journal Articles

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Sabina Chiaretti, MD PhD, Taherinasab Akram, Canichella Martina, Monica Messina, Alfonso Piciocchi, Cyril Šálek, MD PhD, Katerina Machova, Katerina Blagoevova, Jordi Ribera, PhD, Josep-Maria Ribera, MD PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Anna Guarini, PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5211.

https://doi.org/10.1182/blood-2019-122116

Published: 2019

Journal Articles

Natural history and cell of origin of TC F3 - ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL

Clara Bueno, J. Ramón Tejedor, Rachael Bashford-Rogers, Laura González-Silva, Rafael Valdés-Mas, Antonio Agraz-Doblás, Rafael Díaz de la Guardia, Jordi Ribera, Lurdes Zamora, Chrystele Bilhou-Nabera, Nassera Abermil, Hélène Guermouche, Elodie Gouache, Guy Leverger, Mario F. Fraga, Agustín F. Fernández, Paola Ballerini, Ignacio Varela, Pablo Menendez

Blood (2019) 134 (11): 900–905.

https://doi.org/10.1182/blood.2019000893

Published: 2019

Includes: Supplemental data

Journal Articles

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Blood (2018) 132 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2018-99-114559

Published: 2018

Journal Articles

Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials

Blood (2017) 130 (Supplement 1): 1323.

https://doi.org/10.1182/blood.V130.Suppl_1.1323.1323

Published: 2017

Journal Articles

Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics

Ricardo Sanchez, Mireia Morgades, M.Prob.S, Rosa Ayala, Esther Onecha, Yanira Ruiz-Heredia, Jose M. Sanchez, Susana Vives, MD, Santiago Mercadal, MD, Ramón Guardia, Marta Cervera, MD, Olga García, Jordi Ribera, Josep-Maria Ribera, MD, Joaquín Martínez

Blood (2017) 130 (Supplement 1): 2710.

https://doi.org/10.1182/blood.V130.Suppl_1.2710.2710

Published: 2017

Journal Articles

Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 5281.

https://doi.org/10.1182/blood.V128.22.5281.5281

Published: 2016

Journal Articles

Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group

Blood (2014) 124 (21): 3798.

https://doi.org/10.1182/blood.V124.21.3798.3798

Published: 2014

NARROW

Novel Tools to Improve the Challenging Diagnosis of Ph-like ALL. Comparison between Optical Genome Mapping and Digital-MLPA

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Development of a Modified Prognostic Index for Adult Patients with Acute Lymphoblastic Leukemia

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Natural history and cell of origin of TC F3 - ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials

Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics

Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only